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RESEARCH ARTICLE
The economic value of  R0 for selective 
breeding against microparasitic diseases
Kasper Janssen*  and Piter Bijma
Abstract 
Background: Microparasitic diseases are caused by bacteria and viruses. Genetic improvement of resistance to 
microparasitic diseases in breeding programs is desirable and should aim at reducing the basic reproduction ratio R0 . 
Recently, we developed a method to derive the economic value of R0 for macroparasitic diseases. In epidemiologi‑
cal models for microparasitic diseases, an animal’s disease status is treated as infected or not infected, resulting in a 
definition of R0 that differs from that for macroparasitic diseases. Here, we extend the method for the derivation of the 
economic value of R0 to microparasitic diseases.
Methods: When R0 ≤ 1 , the economic value of R0 is zero because the disease is very rare. When R0 . is higher than 
1, genetic improvement of R0 can reduce expenditures on vaccination if vaccination induces herd immunity, or it 
can reduce production losses due to disease. When vaccination is used to achieve herd immunity, expenditures are 
proportional to the critical vaccination coverage, which decreases with R0 . The effect of R0 on losses is considered 
separately for epidemic and endemic disease. Losses for epidemic diseases are proportional to the probability and 
size of major epidemics. Losses for endemic diseases are proportional to the infected fraction of the population at the 
endemic equilibrium.
Results: When genetic improvement reduces expenditures on vaccination, expenditures decrease with R0 at an 
increasing rate. When genetic improvement reduces losses in epidemic or endemic diseases, losses decrease with R0 
at an increasing rate. Hence, in all cases, the economic value of R0 increases as R0 decreases towards 1.
Discussion: R0 and its economic value are more informative for potential benefits of genetic improvement than 
heritability estimates for survival after a disease challenge. In livestock, the potential for genetic improvement is small 
for epidemic microparasitic diseases, where disease control measures limit possibilities for phenotyping. This is not 
an issue in aquaculture, where controlled challenge tests are performed in dedicated facilities. If genetic evaluations 
include infectivity, genetic gain in R0 can be accelerated but this would require different testing designs.
Conclusions: When R0 ≤ 1 , its economic value is zero. The economic value of R0 is highest at low values of R0 and 
approaches zero at high values of R0.
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Microparasitic diseases are diseases that are caused by 
bacteria and viruses. Genetic improvement of resistance 
to microparasitic diseases in breeding programs for live-
stock and aquaculture species is of interest for the same 
reasons as for macroparasitic diseases, as recently dis-
cussed in Janssen et al. [1]. Genetic improvement should 
aim at reducing the risk and severity of disease outbreaks, 
which are both determined by the basic reproduction 
ratio, R0 [2, 3]. However, the definition of R0 is different 
for microparasitic diseases than for macroparasitic dis-
eases, because the disease status of animals is treated dif-
ferently. For most macroparasitic diseases, the number of 
parasites per host can be counted and the severity of the 
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clinical symptoms increases as the number of parasites 
increases [4]. Thus, in epidemiological models for macro-
parasitic diseases, an animal’s disease status is measured 
by the number of macroparasites that it carries, e.g. [5]. 
For most microparasitic diseases, the number of parasites 
per host cannot be recorded. In epidemiological models 
for microparasitic diseases, an animal’s disease status is 
treated as infected or not infected, without any differen-
tiation in the degree of infection. Thus, R0 is defined as 
the expected number of secondary cases produced by 
a typical infected individual in a completely susceptible 
population, during its entire period of infectiousness [6]. 
R0 has a threshold value of 1, below which a disease is 
very rare.
We distinguish two types of microparasitic diseases: 
epidemic and endemic diseases. In epidemic diseases, 
animals become immune after infection, so that an out-
break can occur only once per production cycle. In 
endemic diseases, animals do not become immune after 
infection and can thus be infected multiple times dur-
ing a production cycle. Therefore, we classify epidemic 
diseases as those that lead to incidental outbreaks and 
endemic diseases as those that are virtually always pre-
sent and for which the infected fraction of the popu-
lation varies around its endemic equilibrium [7]. For 
epidemic diseases, the risk and size of major epidemics 
are determined by R0 . For endemic diseases, the level of 
the endemic equilibrium is determined by R0 . When R0 
drops below 1, major epidemics cannot occur and a dis-
ease cannot become endemic. Thus, breeding programs 
should aim at reducing R0 ultimately to become below 
1, at which point the population is no longer affected. 
Therefore, as for macroparasitic diseases, R0 is the appro-
priate breeding goal trait for both epidemic and endemic 
microparasitic diseases [2].
The economic value of R0 needs to be derived to opti-
mize its relative emphasis in the breeding goal. Recently, 
Janssen et  al. [1] presented a method to derive the eco-
nomic value of R0 for macroparasitic diseases. Here, we 
extend their method to microparasitic diseases.
Methods
To derive the economic value of R0 , the relationship 
between costs and R0 must be known. Costs of a disease 
are the sum of expenditures ( E ) on disease control and 
production losses ( L ) [8]. Depending on the disease man-
agement strategy in the population, the economic value 
of R0 can be derived as the partial derivative of E with 
respect to R0 , while L is held constant [1]:
or as the partial derivative of L . with respect to R0 while E 
is held constant:
(1)EV = ∂E/∂R0,
Because a reduction in R0 increases farm profit, its eco-
nomic value is negative. However, for presentation pur-
poses, we ignore the minus sign in the economic value 
throughout the remainder of the text. When vaccina-
tion is possible, genetic improvement of R0 can reduce 
expenditures on vaccination, while losses remain con-
stant. However, when vaccination is not possible, genetic 
improvement of R0 will mainly reduce losses, while 
expenditures are largely unaffected. Thus, vaccination 
is the only expenditure considered in the Methods sec-
tion of this study. In the Discussion, we elaborate on this 
assumption.
Economic value of  R0 when expenditures are reduced
Vaccination is the economic optimum strategy when the 
reduction in losses from vaccination exceeds expendi-
tures on vaccination. Vaccination reduces the fraction of 
susceptible individuals in a population and, thus, reduces 
the number of secondary cases produced by an infected 
individual, without changing R0 . Here, the reproduction 
ratio after vaccination is denoted by Rvacc . The fraction 
of susceptible individuals decreases as vaccination cov-
erage and vaccine effectiveness increase. Hence, Rvacc 
decreases as vaccination coverage and vaccine effective-
ness increase. Vaccination coverage ( vc ) is the proportion 
of the population that is vaccinated. Vaccine effectiveness 
( e ) can be defined either as the relative reduction in sus-
ceptibility of vaccinated animals compared to unvacci-
nated animals, or as the proportion of vaccinated animals 
that remains fully susceptible, while the other part is fully 
resistant. Both definitions of e have the same implications 
for Rvacc . Both vc and e take values between 0 and 1. Rvacc 
is a function of R0 , vc and e [9]:
When Rvacc ≤ 1 , herd immunity is achieved and no 
major outbreak can occur. When herd immunity can 
be achieved, the critical vaccination coverage is the 
minimum proportion of the population that must be 
vaccinated in order to induce herd immunity. In the 
Discussion, we address the effect of uncertainty in the 
estimate of R0 on the critical vaccination coverage. 
The critical vaccination coverage is the economic opti-
mum vaccination coverage, with lower and higher levels 
increasing the costs of the disease (results not shown). 
Because economic values should be derived under opti-
mized management [10], the economic value of R0 is 
derived from the reduction in expenditures on vaccina-
tion at the critical vaccination coverage. We assume that 
expenditures are proportionate to the critical vaccination 
coverage, i.e. that expenditures per vaccinated animal are 
(2)EV = ∂L/∂R0.
(3)Rvacc = R0 · (1− vc · e).
Page 3 of 10Janssen and Bijma  Genet Sel Evol            (2020) 52:3 
constant. The critical vaccination coverage decreases as 
R0 decreases, so expenditures decrease as R0 decreases. 
At the same time, herd immunity sets the losses to zero, 
so there is no need to differentiate between epidemic and 
endemic diseases. Thus, the economic value of R0 can be 
derived from a reduction in expenditures on vaccination 
while losses are kept constant, i.e. when losses are zero. 
The algebra to define expenditures as a function of R0 and 
for the derivation of the economic value of R0 is provided 
in the following.
E is a function of the critical vaccination coverage, 
population size, and expenditures per vaccinated animal. 
The critical vaccination coverage ( vcrit ) is reached when 
Rvacc = 1 . According to [9], rewriting Eq. (3) for Rvacc = 1 
gives:
vcrit increases with R0 . to an asymptote of 1/e , and 
decreases to 1− 1/R0 as e approaches 1. Any vaccina-
tion coverage that is equal to or higher than vcrit induces 
herd immunity. Let N be the population size and let Evacc 
be expenditures per vaccinated animal. Under these 
assumptions, E is a function of R0 as:
From Eqs. (1) and (5), it follows that:
which gives the economic value when a decrease in R0 
reduces expenditures on vaccination.
When the critical vaccination coverage exceeds its 
theoretical maximum value of 1 (Eq. (4)), herd immunity 
( Rvacc ≤ 1) cannot be achieved. Thus, when R0 is high and 
a vaccine’s effectiveness is low, herd immunity cannot be 
achieved regardless of the vaccination coverage. In such 
cases, genetic improvement of R0 reduces losses while 
expenditures are held constant, which is dealt with in the 
sections below, where R0 can be substituted by Rvacc to 
account for the effect of vaccination.
Economic value of  R0 for epidemic diseases when losses 
are reduced
The simplest model for epidemic diseases is a SIR-
model, where animals are classified according to three 
mutually exclusive states: susceptible, infected, and 
recovered [11, 12]. In this model, all animals are sus-
ceptible before a first epidemic. An epidemic can only 
occur after infection from an external source. After 
(4)vcrit = (1− 1/R0)/e.
(5)E = vcrit ·N · Evacc = (1− 1/R0)/e ·N · Evacc.
(6)
EV =
∂E
∂R0
=
∂((1− 1/R0)/e ·N · Evacc)
∂R0
=
N · Evacc
e
·
∂(1− 1/R0)
∂R0
=
N · Evacc
e · R20
,
infection from an external source, susceptible animals 
can become infected and infected animals can recover. 
Neither infected nor recovered animals can become 
susceptible again. Hence, recovered animals have 
acquired full immunity. The term ‘removed’ is some-
times used instead of ‘recovered’ to indicate that these 
animals no longer affect the epidemic.
We assume that losses are proportional to the aver-
age proportion of the population that gets infected 
during a production cycle. In other words, we ignore 
variation in disease tolerance and assume constant 
losses per infected animal. The average proportion of 
the population that gets infected during a production 
cycle is equal to the product of the probability of an 
epidemic in a production cycle and the expected frac-
tion of the population that gets infected in case of an 
epidemic. The probability of an epidemic in a produc-
tion cycle increases with the frequency of infections 
from an external source. Following infection from an 
external source, it leads to either a minor or a major epi-
demic. During a minor epidemic, a negligible fraction of 
the population gets infected and the epidemic dies out 
quickly. During a major epidemic, a significant fraction 
of the population gets infected. Provided that R0 > 1 , 
the probability for a minor epidemic following infec-
tion from an external source is equal to 1/R0 [12]. Thus, 
minor epidemics occur even when R0 > 1 . After a minor 
epidemic, the probability of a (next) epidemic remains 
virtually unchanged because the susceptible fraction of 
the population remains largely unaltered. Since rela-
tively few animals get infected during minor epidemics, 
we ignore the effect of minor epidemics on losses. Infec-
tion from an external source results in a major epidemic 
with probability 11/R0 , i.e. the probability of not result-
ing in a minor epidemic [12]. The final fraction of the 
population that has been infected by the end of a major 
epidemic increases with R0 , to an asymptote of 1 [12]. 
The final fraction of the population that is still suscep-
tible after a major epidemic is too small for a second 
major epidemic to occur. Based on the above, losses can 
be defined as a function of R0 , from which the economic 
value of R0 can be derived, as shown below.
L is a function of the probability of a major epidemic 
in a production cycle, the final fraction of the popula-
tion that has been infected by the end of a major epi-
demic, population size, and production losses per 
infected individual. Let m be the frequency of infec-
tions from an external source per production cycle. The 
probability that a single infection from an external 
source results in a minor epidemic is 1/R0 ; hence the 
probability that all m infections from an external source 
result in a minor epidemic is 
(
1
R0
)m
 . Thus, the probabil-
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ity ( p ) of a major epidemic during a production cycle is 
equal to [12]:
This probability increases with R0 and with m , to an 
asymptote of 1 (Fig. 1a). The final fraction of the popu-
lation that has been infected by the end of a major epi-
demic is denoted by 1− S∞ , where S∞ is the fraction 
of the population that remains susceptible after the 
epidemic has ended, i.e. the fraction that escapes infec-
tion. Following Britton [12]:
This fraction increases with R0, to an asymptote of 
1 (Fig. 1b). Equation  (8) has no algebraic solution, but 
can be solved numerically. Let N be the population size 
and Lind the losses per infected animal. In a SIR-model, 
animals can get infected only once, so that losses can 
be incurred only once per animal. Under these assump-
tions, L is a function of R0 as:
From Eqs. (2) and (9), it follows that:
(7)p(R0)|R0>1 = 1−
(
1
R0
)m
.
(8)1− S∞ = − ln (S∞)/R0.
(9)L(R0) = p(R0) · (1− S∞) ·N · Lind.
(10)
EV =
∂L
∂R0
=
∂(p(R0) · (1− S∞) ·N · Lind)
∂R0
= N · Lind. ·
(
∂p(R0)
∂R0
· (1− S∞)+
∂(1− S∞)
∂R0
· p(R0)
)
,
where
and since R0 = − ln (S∞)1−S∞  , based on Eq. (8),
Equation  (10) gives the economic value of R0 . for epi-
demic diseases when a decrease in R0 reduces losses, 
where the derivative expressions are given in Eqs.  (11) 
and (12), (1− S∞) in Eq. (8), and p(R0) in Eq. (7). Equa-
tion (10) cannot be simplified further.
Economic value of  R0 for endemic diseases when losses are 
reduced
The simplest model for endemic diseases is a SIS-
model, where recovered animals immediately become 
susceptible again. This model assumes that animals do 
not acquire immunity, such that the population con-
sists of susceptible and infected animals only. Provided 
that R0 > 1 and the disease is present, the fractions 
of susceptible and infected animals in the population 
tend towards a dynamic endemic equilibrium. The 
fraction of infected animals at the endemic equilibrium 
increases with R0 , to an asymptote of 1. We assume 
that losses are proportional to the average fraction of 
(11)
∂p(R0)
∂R0
=
m
R
m+1
0
,
(12)
∂(1− S∞)
∂R0
= −
∂S∞
∂R0
=
−1
∂R0/∂S∞
=
−1
∂
(
−
ln (S∞)
1−S∞
)
/∂S∞
=
(S∞ − 1)
2
1/S∞ + ln (S∞)− 1
R0
p
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Fig. 1 a Relationship between R0 and the probability (p) of a major epidemic during a production cycle for different frequencies of infection from 
an external source (m). Solid blue line: m = 1 , red dashed line: m = 3 , green dashed line: m = ∞ . b Relationship between R0 and the final fraction of 
the population that has been infected by the end of a major epidemic ( 1− S∞ ) in epidemic microparasitic diseases. The dashed black line indicates 
the asymptote
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the population that is infected at the endemic equi-
librium. The algebra to define losses as a function of 
R0 and to derive the economic value of R0 is provided 
below.
L is proportional to the fraction of infected animals at 
the endemic equilibrium, population size, and produc-
tion losses per infected animal. Let S∞ be the suscepti-
ble fraction of the population at the endemic equilibrium, 
such that 1− S∞ is the infected fraction at the endemic 
equilibrium. The endemic equilibrium is reached when 
each infected animal infects on average one other animal 
before it becomes susceptible again. Hence, S∞ · R0 = 1 , 
from which it follows that:
which increases with R0 , to an asymptote of 1 (Fig.  2) 
[12]. Let N be again the population size and Lind the pro-
duction losses for an individual if it was infected during 
the entire length of a production cycle. Production losses 
per day are assumed equal for all infected individuals. 
Then, L is determined by the average fraction of the pop-
ulation that is infected during the length of a production 
cycle, regardless of which individuals are infected. Under 
these assumptions, L is a function of R0 , as follows:
From Eqs. (2) and (14), it follows that:
(13)1− S∞ = 1−
1
R0
,
(14)
L(R0) = (1− S∞) ·N · Lind =
(
1−
1
R0
)
·N · Lind.
which gives the economic value of R0 for endemic dis-
eases when a decrease in R0 reduces losses.
Results
Economic value of  R0 when expenditures are reduced
The relationship between R0 and expenditures on vaccina-
tion and between R0 and its economic value are shown in 
Fig. 3a, b, respectively. Expenditures plateau when the entire 
population is vaccinated. For values of R0 for which expen-
ditures are maximum, herd immunity cannot be attained 
and the economic value results from a reduction in losses 
instead. For values of R0 below the maximum level of expen-
ditures, herd immunity can be attained and expenditures 
decrease at an increasing rate when R0 decreases. Hence the 
economic value is relatively high for low values of R0.
Economic value of  R0 for epidemic diseases when losses 
are reduced
The relationship between R0 and losses and between R0 
and its economic value are shown in Fig. 4a, b, respectively. 
Losses decrease when R0 decreases. At low values of R0 , 
losses decrease rapidly with R0 , resulting in a relatively high 
economic value. When R0 is high and there are frequent 
infections from an external source, a major epidemic occurs 
during most production cycles (Fig. 1a), during which vir-
tually the entire population gets infected (Fig. 1b). In such 
cases, losses are rather insensitive to R0 , resulting in the eco-
nomic value being relatively small. Thus, when R0 increases 
to large values, its economic value approaches zero.
For a given value of R0 , losses increase asymptotically 
with the frequency of infection from an external source 
( m ) (Fig. 4a), because the probability of a major epidemic 
increases asymptotically with m (Fig. 1a). When R0 is low, 
the probability of a major epidemic increases more rap-
idly with R0 for high than for low values of m (Fig. 1a). As 
a result, when R0 is low, the economic value increases with 
m (Fig. 4b). When R0 is high, the probability of a major epi-
demic increases more rapidly with R0 for low than for high 
values of m (Fig. 1a). As a result, when R0 is high, the eco-
nomic value decreases with m (Fig. 4b).
Economic value of  R0 for endemic diseases when losses are 
reduced
The relationship between R0 and losses and between R0 
and its economic value are shown in Fig.  5a, b, respec-
tively. Losses decrease when R0 decreases. At low values 
of R0 , losses decrease rapidly with R0 , resulting in a rela-
tively high economic value. When R0 is high, virtually the 
entire population is infected (Fig. 2). In such cases, losses 
(15)
EV =
∂L
∂R0
=
∂
((
1− 1
R0
)
·N · Lind
)
∂R0
=
N · Lind
R20
,
R0
1-
S
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2
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4
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6
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8
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0
Fig. 2 Relationship between R0 and the infected fraction of the 
population ( 1− S∞ ) in endemic microparasitic diseases. The dashed 
black line indicates the asymptote
Page 6 of 10Janssen and Bijma  Genet Sel Evol            (2020) 52:3 
are rather insensitive to R0 , resulting in a relatively small 
economic value. Thus, when R0 increases to large values, 
its economic value approaches zero.
Discussion
This study presents a method to derive the economic 
value of R0 for microparasitic diseases. When R0 ≤ 1 , 
its economic value is zero, because the disease is very 
rare. Otherwise, genetic improvement of R0 can reduce 
expenditures on vaccination if vaccination induces herd 
immunity, or it can reduce production losses. The criti-
cal vaccination coverage decreases with R0 (Eq.  (4)) and 
expenditures decrease proportionally (Fig.  3a). The 
resulting economic value increases as R0 decreases 
towards 1 (Fig. 3b). Both in epidemic and endemic micro-
parasitic diseases, the average fraction of the population 
Fig. 3 Relationship between R0 and a expenditures on vaccination (Eq. (5)), and b the economic value of R0 (Eq. (6)) for microparasitic diseases 
at different levels of vaccine effectiveness ( e ). The dashed black line in a indicates where expenditures are maximum. Solid blue line: e = 0.5 , 
dashed red line: e = 0.75 , dotted green line: e = 1 . Actual units are omitted from the y‑axes because they depend on the number of animals in the 
population and expenditures per vaccinated animal. Note that the minus sign in the economic value is ignored for presentation purposes
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Fig. 4 Relationship between R0 and a losses (Eq. (9)), and b the economic value of R0 (Eq. (10)) for epidemic microparasitic diseases at different 
frequencies of infection from an external source ( m ). The dashed black line in a indicates the asymptote, i.e. maximum losses. Solid blue line: m = 1 , 
dashed red line: m = 3 , dotted green line: m = ∞ . Actual units are omitted from the y‑axes because they depend on the number of animals in the 
population and losses per infected animal. Note that the minus sign in the economic value is ignored for presentation purposes
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that gets infected during a production cycle decreases at 
an increasing rate when R0 decreases towards 1. Result-
ing losses decrease proportionately (Figs.  4a and 5a). 
Hence, the economic value of R0 is relatively high when 
R0 is low (Figs. 4b and 5b). When R0 is high, production 
losses are relatively insensitive to R0 , resulting in a rela-
tively low economic value.
Effect of  R0 on expenditures and losses
We have shown that genetic improvement of R0 can 
reduce the critical vaccination coverage. However, a 
prerequisite to reduce critical vaccination coverage is to 
have reliable estimates of R0 and vaccine effectiveness. 
Methods to estimate R0 are in Dietz [9]. Since estimates 
of R0 are sensitive to underlying assumptions, they may 
be imprecise [9]. Vaccine effectiveness can be evaluated 
directly from the odds ratio for infection in case–control 
studies in the population at large, or it may be approxi-
mated by the evaluation of vaccine efficacy in controlled 
conditions [13, 14]. However, vaccine effectiveness is not 
routinely reported by manufacturers of veterinary vac-
cines [14]. If the actual value of R0 and a vaccine’s effec-
tiveness are uncertain, the critical vaccination coverage 
and its potential reduction after genetic improvement 
of R0 will also be uncertain. Although Britton [12] pro-
vides a method to estimate the standard error of the criti-
cal vaccination coverage, this method does not account 
for uncertainty in vaccine effectiveness. When extra 
expenditures from vaccinating too many animals com-
pared to the critical vaccination coverage are small rela-
tive to potential losses of vaccinating too few animals, a 
reduction in vaccination coverage after genetic improve-
ment of R0 may not be worth the risk. In that case, the 
economic value of R0 will be lower than the theoretical 
value derived with Eq. (6), or it may even be 0.
Janssen et al. [1] argued that genetic improvement of R0 
may reduce losses, or expenditures, or both. Here, only 
losses and expenditures on vaccination were considered, 
while other expenditures were assumed to be constant. 
Expenditures on preventive measures, such as fallowing 
an aquaculture site after each production cycle, are gener-
ally attractive control measures because they act against 
multiple pathogens simultaneously [15]. Therefore, we 
expect a potential reduction in these expenditures to be 
lower than the corresponding reduction in production 
losses, i.e. ∂L/∂E < −1 , such that these expenditures are 
unlikely to be reduced following genetic improvement. 
Disease specific preventive measures, including prophy-
lactic treatment, reduce the value of R0 , while genetic 
improvement of R0 could reduce these expenditures. The 
outcome of this complex interaction is difficult to predict, 
but in general we expect little effect of genetic improve-
ment on expenditures for preventive measures [1]. On 
the other hand, expenditures on curative treatment, e.g., 
drugs, may be reduced following genetic improvement 
of R0 . However, how treatment is applied likely differs 
between livestock and aquaculture. In livestock, treatment 
can generally be applied at the level of the individual when 
infection is detected, e.g., based on clinical signs. Thus, 
expenditures on treatment of infected animals are pro-
portionate to the average number of infected animals and 
they can be included in production losses as part of Lind 
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Fig. 5 Relationship between R0 and a production losses (Eq. (14)), and b the economic value of R0 (Eq. (15)) for endemic microparasitic diseases. The 
dashed black line in a indicates the asymptote, i.e. maximum losses. Actual units are omitted from the y‑axes because they depend on the number 
of animals in the population and losses per infected animal. Note that the minus sign in the economic value is ignored for presentation purposes
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(Eqs. (10) and (15)). In aquaculture, treatment can only be 
applied at a group level (cage, tank, pond, etc.). For epi-
demic diseases, expenditures on treatment are expected 
to be largely proportional to the probability of major 
epidemics and can, therefore, decrease as R0 decreases 
(Fig. 1a). For endemic diseases, treatment can temporar-
ily reduce the infected fraction of the population. After 
treatment, the infected fraction will return to the endemic 
equilibrium until treatment is applied again. Losses could 
be assumed proportional to the mean infected fraction 
over time, while expenditures are proportional to the 
frequency of treatment. If the frequency of treatment is 
constant after genetic improvement, losses decrease pro-
portional to the mean infected fraction, while expendi-
tures are constant. If the frequency of treatment decreases 
after genetic improvement, expenditures decrease and 
losses remain constant. Such scenarios were evaluated 
for endemic macroparasitic diseases in Janssen et al. [1]. 
However, for endemic microparasitic diseases, treatments 
are not expected to be frequent, because antibiotic usage 
is strongly restricted by legislation to avoid development 
of drug-resistant parasites [16].
Potential for genetic improvement
The results of this study indicate that R0 is a useful indica-
tor of the potential economic impact of genetic improve-
ment. Without consideration of the dynamics of disease 
transmission, one cannot predict the result of selec-
tion. For example, Cock et  al. [17] reported on ‘success 
and failure’ of breeding for disease resistance in shrimp. 
They describe the results of selection for improved resist-
ance against the Taura syndrome virus (TSV) and white 
spot syndrome virus (WSSV). Before selection, survival 
after a major outbreak was about 50% for TSV and 2% 
for WSSV. Assuming that infection leads to death, these 
survival rates suggest values for R0 of about 1.4 for TSV 
and 4 for WSSV (Eq. (8)). A few generations of selection 
for resistance to TSV returned survival to levels similar 
to those before the disease was introduced, while selec-
tion for resistance to WSSV had disappointing results. 
Selection procedures for both diseases were similar and 
the authors of this study had difficulties to explain these 
apparently contrasting results. However, given the above 
estimates of R0 , such results are not surprising. The low 
value of R0 for TSV suggests that survival after a major 
epidemic can be improved rapidly, while the higher value 
of R0 for WSSV suggests that improvement is expected 
to occur at a much slower pace (Fig. 1b). For the above 
estimates of R0 , a 30% improvement would be sufficient 
to eradicate TSV, while the same improvement would 
increase survival after a major epidemic of WSSV to 
only 7.5%. This example illustrates that an estimate of 
heritability is not sufficient to evaluate the potential for 
economic gain of selection for resistance to a specific dis-
ease, because it ignores that resistant animals no longer 
infect other animals [2]. An estimate of R0 , ideally com-
bined with its economic value, is at least as important. 
Although there are numerous estimates of heritability for 
resistance to specific diseases in aquaculture [18, 19], R0 
and its economic value are rarely considered. When R0 is 
low, its economic value is likely high, whereas when R0 
is high, its economic value is likely low (Figs. 3b, 4b and 
5b). Thus, even in the absence of genetic parameters, R0 
and its economic value can be used as the first criteria to 
judge the potential benefits of selection for resistance to 
a specific disease. However, in the literature, estimates 
of R0 vary considerably. For example, estimates of R0 for 
WSSV vary from 1.51 [20] to 93 [21], which makes direct 
interpretation impossible. Thus, consensus and standard-
ization on estimation of R0 in epidemiology are required.
Use of epidemiological models
Previous studies on livestock have demonstrated the 
need to account for the dynamics of disease transmission 
to predict the response to selection. For example, for an 
epidemic microparasitic disease in pigs, MacKenzie and 
Bishop [22] predicted that the final fraction of the popu-
lation that will be infected by the end of a major epidemic 
decreases at an increasing rate with decreasing values of 
R0 , just as in Fig. 1b. Similarly, Nieuwhof et al. [23] pre-
dicted a substantially higher response in prevalence for 
an endemic microparasitic disease in sheep when using 
epidemiological models than when using prevalence as 
a predictor in a threshold model. These studies demon-
strate the need to account for the dynamics of disease 
transmission in the derivation of the economic value of 
disease resistance, as also discussed in Janssen et al. [1].
The models used in this study describe within-farm 
dynamics of disease transmission. However, genetic 
improvement of R0 may also affect the dynamics of disease 
transmission between farms. In Eq. (7), the probability of a 
major epidemic during a production cycle is a function of 
R0 and the frequency of infection from an external source, 
which was assumed to be constant. The source of these 
infections can be the natural environment or neighbour-
ing farms. Thus, when R0 in neighbouring farms improves, 
disease prevalence on these farms may decrease, reducing 
the frequency of infection from an external source. Conse-
quently, the probability of a major epidemic would decrease 
more rapidly after genetic improvement of R0 , which would 
increase its economic value. To adequately account for the 
effect of R0 on the frequency of infection from an external 
source, a combined within- and between-farm epidemio-
logical model would be required, e.g., as in Aldrin et al. [24].
For aquatic environments, it has been questioned to 
what extent traditional epidemiological models are valid, 
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including the SIR and SIS-models used here. These mod-
els have been largely developed for terrestrial popula-
tions, where disease transmission occurs on a relatively 
small spatial scale. In an aquatic environment, disease 
transmission can occur without direct contact between 
animals since pathogens can spread over relatively large 
distances in the water column [25, 26]. Disease dynamics 
on large spatial scales such as those between farms, may, 
therefore, be fundamentally different in aquaculture than 
in livestock. However, for within-farm disease dynam-
ics, indirect transmission via the water column can be 
accounted for in the transmission rate parameter [20] of 
the SIR and SIS models.
Genetic evaluation of  R0
In livestock, drastic control measures are taken at a 
regional level as soon as some epidemic microparasitic 
diseases, such as classical swine fever and foot-and-
mouth disease, are detected [27]. Since such control 
strategies limit routine phenotyping options in breeding 
programs [28], genetic improvement of R0 is not feasible 
for many epidemic microparasitic diseases in livestock. 
For endemic diseases, longitudinal data on the disease 
status of individual animals in farms can sometimes be 
used. For example, Biemans, et al. [29] estimated breed-
ing values for R0 for digital dermatitis from longitudinal 
data on cows in 12 dairy farms.
In aquaculture, phenotyping for microparasitic dis-
eases is not an issue when controlled challenge tests 
can be performed in dedicated facilities. In a chal-
lenge test, naive fish are exposed to the pathogen via 
submersion, injection or cohabitation with infected 
‘donor’ fish. After some incubation time, phenotypes 
are recorded as dead or alive. Dead fish are considered 
susceptible and surviving fish resistant [19]. To maxi-
mize phenotypic variation, the endpoint of the chal-
lenge test is sometimes chosen such that the survival 
rate is 50% [30]. There are, however, two main issues 
with this dead-or-alive phenotype. First, incomplete 
exposure obscures the phenotypic expression of sus-
ceptibility [19]. In any epidemic, some animals may 
not get infected because they escaped infection due to 
chance, rather than because they were less susceptible. 
When the endpoint of the challenge test is set retro-
spectively to the point at which the survival rate was 
50%, the number of obscured phenotypes increases. 
Second, with a dead-or-alive phenotype, susceptibility 
and tolerance are confounded, while only susceptibility 
is of interest when the objective is to improve R0 . Thus, 
analyses of binomial survival in threshold models can 
provide inadequate proxies of susceptibility [31].
Current challenge tests in aquaculture, as described 
above, capture genetic variation in susceptibility at best, 
leaving genetic variation in infectivity unexploited. Since 
susceptibility and infectivity have multiplicative effects 
on R0 , genetic gain in R0 can be accelerated when both 
susceptibility and infectivity are included in genetic 
evaluations [2, 32, 33]. Anche et  al. [2] have described 
how estimated breeding values (EBV) for susceptibil-
ity and infectivity can be combined into a single EBV for 
R0 . Furthermore, the accuracy of EBV for susceptibility 
improves when infectivity is included in the model for 
genetic evaluation [34, 35]. The inclusion of infectivity 
in genetic evaluation requires testing designs that differ 
from the currently used challenge tests, as discussed in 
the following.
The same testing design can be used for epidemic and 
endemic diseases, because the objective is genetic evalu-
ation of R0 rather than a characterisation of the disease. 
To capture genetic variation in infectivity, some indi-
viduals should be infected (and, therefore, become infec-
tious) while others are susceptible. Thus, at the start of 
a challenge test, only some animals should be artificially 
infected, after which the disease is allowed to spread 
naturally [34]. Then, the disease status of each animal, 
infected or not, must be recorded over the course of the 
epidemic. Although longitudinal data are required, the 
sampling frequency does not need to be high, because 
infection times can be predicted from relatively few sam-
ple points [34]. For a fixed total number of samplings, 
Biemans et  al. [29] found that the optimum interval 
between samplings lies between 25 and 50% of the dura-
tion of the infectious period. Multiple epidemic groups 
are required, with related individuals distributed between 
groups [2], although the optimal group structure has not 
yet been studied [29]. For a given testing capacity, hav-
ing fewer larger groups favours the estimation of sus-
ceptibility, whereas having many smaller groups tends 
to produce better estimates of infectivity [34]. For a SIS 
model, prediction accuracies for additive genetic effects 
and heritability estimates improve as disease prevalence 
increases [34], but this has not been studied for a SIR 
model. Recently, an experimental design that followed 
the above considerations was used for the genetic evalu-
ation of susceptibility and infectivity for a macroparasitic 
disease [36]. This study successfully demonstrated pres-
ence of genetic variation in infectivity but did not obtain 
estimates of genetic parameters and breeding values.
Conclusions
This study presents a method to derive the economic 
value of R0 for microparasitic diseases. When R0 ≤ 1 , 
the economic value is zero, because the disease is very 
rare. When genetic improvement of R0 reduces expen-
ditures on vaccination, the economic value increases as 
R0 decreases towards 1. The effect of R0 on production 
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losses differs between epidemic and endemic micropara-
sitic diseases. Nevertheless, when genetic improvement 
of R0 reduces losses, the economic value is highest at low 
values of R0 for both epidemic and endemic micropara-
sitic diseases, while it approaches 0 at high values of R0.
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